On Friday, Janux Therapeutics Inc (NASDAQ: JANX) was -4.58% drop from the session before settling in for the closing price of $51.10. A 52-week range for JANX has been $7.79 – $65.60.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 32.66%. When this article was written, the company’s average yearly earnings per share was at -4.86%. With a float of $42.00 million, this company’s outstanding shares have now reached $46.25 million.
The extent of productivity of a business whose workforce counts for 64 workers is very important to gauge. In terms of profitability, gross margin is 87.98%, operating margin of -658.76%, and the pretax margin is -463.91%.
Janux Therapeutics Inc (JANX) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Janux Therapeutics Inc stocks. The insider ownership of Janux Therapeutics Inc is 19.32%, while institutional ownership is 86.59%. The most recent insider transaction that took place on Nov 01 ’24, was worth 277,987. Before that another transaction happened on Nov 01 ’24, when Company’s FORMER DIRECTOR proposed sale 1,139 for $53.31, making the entire transaction worth $60,723.
Janux Therapeutics Inc (JANX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -4.86% per share during the next fiscal year.
Janux Therapeutics Inc (NASDAQ: JANX) Trading Performance Indicators
You can see what Janux Therapeutics Inc (JANX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 38.80. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 187.11.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.18, a number that is poised to hit -0.39 in the next quarter and is forecasted to reach -1.70 in one year’s time.
Technical Analysis of Janux Therapeutics Inc (JANX)
The latest stats from [Janux Therapeutics Inc, JANX] show that its last 5-days average volume of 0.61 million was inferior to 0.71 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 10.67%. Additionally, its Average True Range was 2.87.
During the past 100 days, Janux Therapeutics Inc’s (JANX) raw stochastic average was set at 60.51%, which indicates a significant increase from 4.32% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 31.31% in the past 14 days, which was lower than the 53.50% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $49.76, while its 200-day Moving Average is $42.91. Now, the first resistance to watch is $50.45. This is followed by the second major resistance level at $52.15. The third major resistance level sits at $53.20. If the price goes on to break the first support level at $47.70, it is likely to go to the next support level at $46.65. Assuming the price breaks the second support level, the third support level stands at $44.95.
Janux Therapeutics Inc (NASDAQ: JANX) Key Stats
There are 52,482K outstanding shares of the company, which has a market capitalization of 2.44 billion. As of now, sales total 8,080 K while income totals -58,290 K. Its latest quarter income was 440 K while its last quarter net income were -28,060 K.
